- Polyrizon Ltd. has signed an agreement with a global preclinical CRO to conduct biocompatibility studies supporting its clinical development program.
- The studies, expected to begin in Q2 2026, are designed to support regulatory submissions and enable planned clinical trials later in the year.
Polyrizon Ltd. has entered into an agreement with a global preclinical contract research organization (CRO) to conduct biocompatibility studies as part of its clinical development program. The CRO will perform testing aligned with ISO 10993 standards and Good Laboratory Practice (GLP) requirements to support regulatory submissions.
The studies are expected to begin in the second quarter of 2026 and represent a key step in the company’s regulatory pathway toward initiating clinical trials later this year. The program includes assessments such as cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, and pyrogenicity to evaluate product safety prior to human studies.
The agreement forms part of Polyrizon’s broader development roadmap, which also includes recent Good Manufacturing Practice (GMP) production of clinical trial materials, completion of an FDA pre-submission meeting, and preclinical data indicating allergen-blocking performance.
Polyrizon is a pre-clinical-stage biotechnology company developing intranasal hydrogel-based medical devices designed to form a barrier in the nasal cavity to block viruses and allergens. The CRO collaboration is intended to generate the safety data required to progress these products into clinical evaluation.
“This agreement marks an important step in the advancement of our development program.”
Tomer Izraeli, Chief Executive Officer of Polyrizon
Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing. 
